UsAgainstAlzheimer’s Statement on Crenezumab
UsAgainstAlzheimer's Chairman George Vradenburg issued the following statement today regarding the termination of clinical trial testing of the Alzheimer's drug crenezumab by Roche and AC Immune.
“Today’s announcement is very disappointing, especially for the millions of Americans living with Alzheimer’s disease. Our commitment to patients, caregivers, and the entire Alzheimer’s community persists. Too many patients and their families are waiting for better treatments and a cure. For a country that has ‘cured the incurable’ before, the waiting must end.
“To the participants and families in this trial we say thank you. Your role as citizen scientists is vital to advancing our understanding of the disease and accelerating treatments and cures.
“We commend Roche and AC Immune for their commitment to help the 5.7 million people in the U.S. and more than 50 million worldwide living with Alzheimer’s today.
“Across industry and the healthcare system, we must increase our investment so that we can take as many shots on goal as possible to beat Alzheimer’s. We’ve waited long enough.”